Health Professional Radio - Podcast

Dr. Steve Shak, Chief Medical Officer at Exact Sciences discusses the publication of new analyses of two clinical studies that demonstrate for the first time the value of the Oncotype DX Genomic Prostate Score® (GPS™) test in guiding treatment plans in patients with unfavorable intermediate (UFI)-risk prostate cancer. The study, published in "Urology", validates the GPS test as a strong independent predictor of critical endpoints in UFI-risk prostate cancer patients, suggesting its benefit in personalizing and improving treatment decisions.